Stock Track | Fulgent Genetics Plunges Over 5% After Disappointing Q3 Earnings

Stock Track11-08

Shares of Fulgent Genetics Inc. (NASDAQ: FLGT) plummeted over 5% on Wednesday, November 8, 2024, after the company reported its financial results for the third quarter of 2024.

The genetic testing company posted total revenue of $71.7 million for the quarter, with its core revenue (excluding COVID-19 testing) growing 9% year-over-year to $71.7 million. However, the company reported a net loss of $14.6 million, or $0.48 per share, compared to a net loss of $13.1 million in the same period last year.

Despite the revenue growth, Fulgent's adjusted EBITDA income for the quarter was a mere $0.4 million, indicating weak profitability. The company also posted a non-GAAP operating loss of $4.2 million, with a negative operating margin of 5.8%.

While Fulgent reiterated its full-year 2024 core revenue guidance of $280 million and improved its earnings per share guidance, investors appeared to be disappointed with the company's lacklustre bottom-line performance in the third quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124989013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124989013","market":"hk","top_or_hot":-1,"title":"Stock Track | Fulgent Genetics Plunges Over 5% After Disappointing Q3 Earnings","media":"Stock Track","content":"<p>Shares of Fulgent Genetics Inc. (NASDAQ: FLGT) plummeted over 5% on Wednesday, November 8, 2024, after the company reported its financial results for the third quarter of 2024.</p>\n\n<p>The genetic testing company posted total revenue of $71.7 million for the quarter, with its core revenue (excluding COVID-19 testing) growing 9% year-over-year to $71.7 million. However, the company reported a net loss of $14.6 million, or $0.48 per share, compared to a net loss of $13.1 million in the same period last year.</p>\n\n<p>Despite the revenue growth, Fulgent's adjusted EBITDA income for the quarter was a mere $0.4 million, indicating weak profitability. The company also posted a non-GAAP operating loss of $4.2 million, with a negative operating margin of 5.8%.</p>\n\n<p>While Fulgent reiterated its full-year 2024 core revenue guidance of $280 million and improved its earnings per share guidance, investors appeared to be disappointed with the company's lacklustre bottom-line performance in the third quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Fulgent Genetics Plunges Over 5% After Disappointing Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Fulgent Genetics Plunges Over 5% After Disappointing Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 22:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Fulgent Genetics Inc. (NASDAQ: FLGT) plummeted over 5% on Wednesday, November 8, 2024, after the company reported its financial results for the third quarter of 2024.\nThe genetic testing ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"","article_id":"1124989013","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124989013","pubTimestamp":1731076661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Fulgent Genetics Inc.  plummeted over 5% on Wednesday, November 8, 2024, after the company reported its financial results for the third quarter of 2024.The genetic testing company posted total revenue of $71.7 million for the quarter, with its core revenue  growing 9% year-over-year to $71.7 million. However, the company reported a net loss of $14.6 million, or $0.48 per share, compared to a net loss of $13.1 million in the same period last year.Despite the revenue growth, Fulgent's ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics第三季度盈利令人失望后股价暴跌超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":1},"content_text":"Shares of Fulgent Genetics Inc. (NASDAQ: FLGT) plummeted over 5% on Wednesday, November 8, 2024, after the company reported its financial results for the third quarter of 2024.\nThe genetic testing company posted total revenue of $71.7 million for the quarter, with its core revenue (excluding COVID-19 testing) growing 9% year-over-year to $71.7 million. However, the company reported a net loss of $14.6 million, or $0.48 per share, compared to a net loss of $13.1 million in the same period last year.\nDespite the revenue growth, Fulgent's adjusted EBITDA income for the quarter was a mere $0.4 million, indicating weak profitability. The company also posted a non-GAAP operating loss of $4.2 million, with a negative operating margin of 5.8%.\nWhile Fulgent reiterated its full-year 2024 core revenue guidance of $280 million and improved its earnings per share guidance, investors appeared to be disappointed with the company's lacklustre bottom-line performance in the third quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124989013"}